Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report

Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report

Saved in:

Bibliographic Details
Main Authors:	Hua-Yang Pang, Meng-Yua Yan, Xiu-Feng Chen, Hao Sun
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Asian Journal of Surgery
Subjects:	Metastatic colorectal cancer HER2-positive Neoadjuvant treatment Pathologic complete response
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958424015082
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Zoledronic-acid plus neoadjuvant therapy is associated with provoking outcomes in Her2-positive breast cancer
by: Bruno de Paula, et al.
Published: (2025-01-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment
by: Laura Sun, et al.
Published: (2024-12-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)

CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients
by: Weibo Kong, et al.
Published: (2024-12-01)

A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report
by: Haijuan Yu, et al.
Published: (2024-11-01)

The impact of preoperative treatment on mismatch repair protein and HER2 expression in colorectal cancer: an analysis of paired samples
by: Zhen Chen, et al.
Published: (2024-11-01)

Research trends of neoadjuvant therapy for breast cancer: A bibliometric analysis
by: Laiping Xie, et al.
Published: (2025-12-01)

Radiomics of magnetic resonance imaging for assessment of pathological complete response to neoadjuvant therapy and long-term survival in breast cancer
by: N. V. Petrova, et al.
Published: (2023-09-01)

Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers‐Based Model
by: Maria Colomba Comes, et al.
Published: (2024-12-01)

Predictive factors for axillary pathological complete response to neoadjuvant therapy in elderly breast cancer patients
by: Yuying Wang, et al.
Published: (2025-01-01)

Nodal involvement in patients with small, clinically node-negative HER2-positive breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy
by: Josefien P. van Olmen, et al.
Published: (2024-12-01)

Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges
by: Marie Brevet, et al.
Published: (2024-12-01)

Carcinoembryonic antigen trajectory predicts pathological complete response in advanced gastric cancer after neoadjuvant chemotherapy
by: Yonghe Chen, et al.
Published: (2025-02-01)

Update on Diagnosis and Treatment of Colorectal Cancer
by: Chan Wook Kim
Published: (2022-10-01)

The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis
by: Shiwei Liu, et al.
Published: (2025-01-01)

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression
by: Yunus Emre Altıntaş, et al.
Published: (2024-12-01)

Total neoadjuvant therapy based on short-course radiotherapy versus standard long-course chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of randomized controlled trials
by: Wenji Pu, et al.
Published: (2024-12-01)

Corrigendum: Total neoadjuvant therapy based on short-course radiotherapy versus standard long-course chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of randomized controlled trials
by: Wenji Pu, et al.
Published: (2025-01-01)

PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials
by: A. Cammarota, et al.
Published: (2024-12-01)

Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the NetherlandsResearch in context
by: Hanneke van Laarhoven, et al.
Published: (2025-02-01)

Dynamic changes in serum adenosine and the adenosine metabolism-based signature for prognosis in HER2-positive metastatic breast cancer patients
by: Lijun Wang, et al.
Published: (2024-12-01)

Impact of pathological complete response on survival in gastric cancer after neoadjuvant chemotherapy: a propensity score matching analysis
by: Yonghe Chen, et al.
Published: (2025-01-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Predictive and Prognostic Value of Inflammatory and Nutritional Indexes in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Mustafa Ozgur Arici, et al.
Published: (2024-11-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections.
by: Miguel Figallo, et al.
Published: (2024-01-01)

Significant Pathologic Response Following Neoadjuvant Therapy and Curative Resection in Patients With Rectal Cancer: Surgical and Oncological Outcomes From a Retrospective Cohort Study
by: Fatemeh Shahabi, et al.
Published: (2024-11-01)

Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study
by: Hai Zhang, et al.
Published: (2025-01-01)

Case report: Watch-and-wait strategy in resectable esophageal cancer following neoadjuvant chemoimmunotherapy: a case series
by: Lingyu Tan, et al.
Published: (2025-01-01)

Magnetic resonance imaging‐based radiomics nomogram for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high‐risk non‐metastatic prostate cancer
by: Xiao‐Hui Wu, et al.
Published: (2024-07-01)

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study
by: Yan Chen, et al.
Published: (2024-12-01)

Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis
by: Huan Zhang, et al.
Published: (2025-01-01)

Combined morphology and radiomics of intravoxel incoherent movement as a predictive model for the pathologic complete response before neoadjuvant chemotherapy in patients with breast cancer
by: Yunyan Zheng, et al.
Published: (2025-02-01)

Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy
by: Hanhan Li, et al.
Published: (2025-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Neoadjuvant therapy in rectal cancer—one year follow-up results of standard versus total neoadjuvant strategies
by: Luís Correia Gomes, et al.
Published: (2024-11-01)

Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials
by: Shihui Hu, et al.
Published: (2024-11-01)

Relationship of Neoadjuvant Chemotherapy Efficacy with Histopathologic Molecular Subtypes in Breast Cancer Patients
by: Çiğdem Yıldırım, et al.
Published: (2024-11-01)